

INTERNATIONAL INVASIVE LOBULAR BREAST CANCER (ILC) SYMPOSIUM 2023 PITTSBURGH, PA – SEPTEMBER 28-30, 2023

| THURSDAY, SEPTEMBER 28 TH | | | |
|---|--|--|--|
| 7:00am-8:00am | Registration and Breakfast | | |
| ILC Workshops | ILC Workshops | | |
| Moderator: Emilia Diego, MD (UPMC, Pittsburgh, PA), Lori Petitti (Independent ILC Advocate), Claire Turner (Lobular Breast Cancer UK) | | | |
| 8:00am-8:50am | Session 1: Overview: Basic Science and Biology of ILC and Clinical Consideration of Primary/Early Stage ILC | | |
| 8:55am-9:45am | Session 2: Metastatic ILC: Current Treatment Strategies and Imaging | | |
| 9:45am-10:00am | Coffee Break | | |
| 10:05am-10:45am | Session 3: Progress in ILC Advocacy | | |
| 10:50am-11:35am | Session 4: Communications and Social Media: Communication Tips, Telling your story and more | | |
| 11:35am-12:30pm | Lunch | | |
| 12:30pm-12:35pm | Introduction to International Invasive Lobular Breast Cancer Symposium 2023 Steffi Oesterreich, PhD (UPMC Hillman Cancer Center, Pittsburgh, PA), Robert Ferris, MD, PhD (UPMC Hillman Cancer Center, Pittsburgh, PA) | | |
| 12:35pm-12:45pm 12:45pm-1:30pm | Introduction by: Flora Migyanka (Breast Cancer Advocate, Dynami), and Anne Vincent-Salomon, MD, PhD (Institut Curie, Paris, France) Keynote: Stuart Schnitt, MD (Dana-Farber Cancer Institute, Boston, MA) – The Leigh Pate Memorial Lectureship on Lobular Breast Cancer <i>Invasive Lobular Carcinoma: Where Have We Been and Where Are We Going?</i> | | |
| 1:30pm | Session 1: Pathology, Diagnosis, ILC Variants and Lobular Neoplasia Chair: Rohit Bhargava, MD (UPMC Magee-Womens Hospital, Pittsburgh, PA) | | |
| 1:35pm-1:55pm | Maxim De Schepper, MD, PhD (KU Leuven, Belgium) Homogenization of Pathological Diagnosis of ILC | | |
| 1:55pm-2:15pm | Tari King, MD (Dana-Farber Cancer Institute, Boston, MA) Lobular Carcinoma In Situ – Current Concepts and Challenges | | |
| 2:15pm-2:30pm | Oral presentation selected from Abstract submissions: Lounes Djerroudi, MD (Institut Curie, Paris) E-cadherin inactivation shapes tumor microenvironment specificities in ILC | | |

| 2:30pm-2:45pm | Oral presentation selected from Abstract submissions: |
|---------------|---|
| | Osama Shah, PhD (UPMC Hillman Cancer Center) |
| | <i>Spatial profiling of mixed invasive ductal-lobular carcinoma reveals intrinsic molecular subtype and oncogenic signaling heterogeneity</i> |
| 2:45pm-3:05pm | Coffee Break |
| 3:05pm | Session 2: E-cadherin and the ILC Tumor Microenvironment |
| | Chair: Rebecca Riggins, PhD (Georgetown University, Washington, DC) |
| 3:10pm-3:30pm | Patrick Derksen, PhD (UMC Utrecht, Netherlands) |
| 5.10pm-5.50pm | E-cadherin to F-actin Linkage Reveals Candidate Tumor Suppressors in Lobular Breast Cancer |
| 3:30pm-3:50pm | Val Brunton, PhD (University of Edinburgh Scotland) |
| 5.50pm-5.50pm | Cancer-Associated Fibroblasts in the ILC Microenviroment |
| | Special Session: Signaling by Adhesion and Growth Factor Receptors. Their Role in |
| 3:50pm | ILC Biology and Treatment |
| | Chair: Patrick Derksen, PhD (UMC Utrecht, Netherlands) |
| | Special Lecture |
| 3:55pm-4:25pm | Yossi Yarden, PhD (Dwek Institute for Cancer Therapy Research, Rehovot, Israel) |
| | Regulation of Metastasis and Dormancy by Nucleo-cytoplasmic Transport and Redox Potential |
| 4:25pm-4:45pm | Thijs Koorman, PhD (UMC Utrecht, Netherlands) |
| 4.25pm-4.45pm | Targeting Survival Cues to Treat Lobular Breast Cancer |
| 4:45pm-5:05pm | Ariella Hanker, PhD (University of Texas Southwestern, Dallas, TX) |
| | Therapeutic Targeting of HER2 Drive Mutations in ILC |
| 5:05pm-5:25pm | Rinath Jeselsohn, MD (Dana-Farber Cancer Institute, Boston, MA) |
| | A unique chromatin state drives therapeutic resistance in ILC |
| 5:25pm-7:00pm | Poster Session (wine and cheese served) |
| 7:00pm | Dinner on your own. |
| | ** Special Event: Dinner and Entertainment at Gateway Clippers fleet. Requires separate registration for the event. Please check registration details on the symposium website under <u>social activities.</u> |

| FRIDAY, SEPTEMBER 29 TH | | |
|------------------------------------|---|--|
| 7:00am-7:30am | Yoga (optional). Additional details on the symposium website under <u>social activities.</u> | |
| 7:30am-8:30am | Breakfast | |
| 8:30am-8:35am 8:35am-9:10am | Introduction by: Leonie Young, PhD (RCSI, Dublin, Ireland)Keynote: Cathrin Brisken, MD, PhD (Swiss Federal Institute of Technology Lausanne, Switzerland, The Institute of Cancer Research, London, UK)A new look at lobular carcinoma development: through the teat | |
| 9:15am | Session 3: Modeling ILC | |

| | Chair: Sean Egan, PhD (University of Toronto, Canada) |
|-----------------|--|
| 9:20am-9:40am | Adrian Lee, PhD (UPMC Hillman Cancer Center, Institute for Precision Medicine. Pittsburgh, PA) <i>Understanding ILC models</i> |
| 9:40am-10:00am | Damir Vareslija, PhD (Royal College of Surgeons, Dublin, Ireland) <i>Exploring New Targets: Molecular Profiling of Metastatic Patient-Derived Models</i> |
| 10:00am-10:15am | Oral presentation selected from Abstract submissions: Christina L. Gersch, BS, BSN (University of Michigan, Michigan) Characterization of Resistance to CDK4/6 Inhibitors and Endocrine Therapy in Invasive Lobular Breast Cancer Cell Lines |
| 10:15am-10:35am | Coffee Break |
| 10:35am | How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research – In Memory of Leigh Pate |
| 10:40am-10:50am | Steffi Oesterreich, PhD (University of Pittsburgh, UPMC Hillman Cancer Center) <i>Leigh Pate: How it all started</i> |
| 10:50am-10:55am | Lori Petitti (Independent ILC Advocate) The Genesis of the Lobular Breast Cancer Alliance |
| 10:55am-11:00am | Diane Mapes (Independent ILC Advocate) Leigh Pate: A short life, a long view |
| 11:00am-11:05am | Flora Migyanka (Independent Advocate/Founder, Dynami Foundation) <i>How one person sparked a movement</i> |
| 11:05am-11:10am | Siobhan Freeney (Lobular Ireland) Sowing the seeds of Change' - Leigh's Legacy. |
| 11:10am-11:15am | Claire Turner (Lobular Breast Cancer UK) Leaning In with Lobular |
| 11:15am-11:25am | Matt Sikora, PhD (University of Colorado Denver, Anschutz Medical Campus, Denver, CO) <i>Building Bridges in Research Outreach and Lobular Cancer Biology</i> |
| 11:25am-11:35am | Jagmohan Hooda, PhD, MBA (UPMC Hillman Cancer Center, Pittsburgh, PA) BCRF ILC Legacy Project – Lobular Breast Cancer Biobank |
| 11:35am –1:00pm | Lunch and Poster Session |
| 1:00pm-1:40pm | Panel Discussion – Diversity, Equity, Inclusion, Justice (DEIJ) Aspects in ILC Research, Treatment and Advocacy Chair: Stephanie Walker (MBCI Advocate, MBC Alliance-Become Project) Advisor: Julia Maues (Breast Cancer Advocate, GRASP) Panel Members: Kathryn Demanelis, PhD (UPMC Hillman Cancer Center, Pittsburgh, PA), Claire Turner (Lobular Breast Cancer UK), Yen Lam, Myiesha Gibson, Ma'isah Wise (all independent advocates) |
| 1:45pm | Session 4: Unique Imaging Modalities in ILC Chair: Vincent Vandecaveye, MD, PhD (KU Leuven, Belgium) |

| 1:50pm-2:10pm | Matthew Covington, MD (University of Utah, Salt Lake City) Challenges and Potential Solutions for Imaging of Invasive Lobular Carcinoma |
|---------------|---|
| 2:10pm-2:30pm | Hannah Linden, MD, FACP (Fred Hutch Cancer Center, University of Washington, Seattle) Imaging and ILC, Advances and Opportunities |
| 2:30pm-2:50pm | Gary Ulaner, MD (Hoag Family Cancer Institute, University of Southern California, Irvine) <i>Estrogen Receptor (ER)-targeted PET: Clinical Applications and Interpretation</i> |
| 2:50pm-3:10pm | Vincent Vandecaveye, MD, PhD (Katholieke Universiteit Leuven, Belgium) Whole Body Diffusion-Weighted MRI in Lobular Breast Cancer: Development and Clinical Applications for Staging and Response Assessment |
| 3:10pm-3:30pm | Coffee |
| 3:30pm | Session 5: Genetics of ILC –Use of clinical specimens and data Chair: Elinor Sawyer, PhD (Kings College, London, UK) |
| 3:35pm-3:55pm | Giovanni Corso, MD, PhD (European Institute of Oncology, University of Milan, Italy) Hereditary lobular breast cancer syndrome associated with germline CDH1 variants |
| 3:55pm-4:15pm | Ethan Sokol, PhD (Foundation Medicine, Boston, MA) <i>Identification of Targetable Vulnerabilities in ILC Using Comprehensive Genomics Profiling</i> |
| 4:15pm-4:35pm | Maria Margarete Karsten, MD, PhD (Charité-Universitatsmedizin Berlin, Germany) IDA – How an Individualized Digital Aid for ILC Can Assist Patients and Research |
| 4:35pm | Session 6: Challenges in Treatment of ILC Chair: Vikram Gorantla, MD (UPMC, Pittsburgh) |
| 4:40pm-5:00pm | Suzanne Fuqua, PhD (Baylor College of Medicine, Houston) When the Breast Cancer Researcher Becomes the Patient with ILC |
| 5:00pm-5:20pm | Jason Mouabbi, MD (University of Texas, MD Anderson Cancer Center, Houston) Differential Genomic and Transcriptomic Analysis of Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma |
| 5:20pm-5:40pm | Julia Foldi, MD, PhD (University of Pittsburgh, UPMC, Pittsburgh, PA) Distinct features of ILC vs IDC in four NSABP randomized trials of adjuvant chemotherapy |
| 5:40pm-6:00pm | Kathryn Schmitz, PhD, MPH (University of Pittsburgh, UPMC Hillman Cancer Center, PA) <i>Exercise is Medicine in the Setting of Oncology</i> |
| 6:10pm | Dinner on your own. **Special Event: Baseball game night for attendees. Requires separate registration for the event. Please check registration details on the symposium website under <u>social</u> <u>activities</u> . |

| SATURDAY, SEPTEMBER 30 TH | |
|--------------------------------------|---|
| 7:30am-8:50am | Round Table Clinical and Scientific Discussions Over Breakfast |
| 8:55am | Session 7: Local Treatment of ILC |

| | Chair: Bhuvaneswari Ramaswamy, MD (The Ohio State, Columbus, OH) |
|-----------------|--|
| 9:00am-9:20am | Rita Mukhtar, MD (UCSF, San Francisco, CA) |
| | Surgical management of ILC: challenges and opportunities |
| 9:20am-9:40am | Priscilla McAuliffe, MD, PhD (UPMC Magee-Womens Hospital and UPMC Hillman Cancer Center, Pittsburgh, PA) |
| | Surgical management of the axilla in lobular cancer. |
| 0:40.2m | Session 8: Treatment Resistance and Metastases |
| 9:40am | Chair: Fresia Pareja, MD, PhD (Memorial Sloan Kettering Cancer Center, NYC, NY) |
| 9:45am-10:05am | Massimo Cristofanilli, MD (Sandra Edward Meyer Cancer Center, Weill Cornell, NYC, NY) |
| | Liquid biopsy in ILC: What can we learn about clinical and molecular evolution? |
| 10:05am-10:25am | Peter Simpson, PhD (University of Queensland, Australia) <i>ILC-focused biomarkers of progression and prognosis</i> |
| | Karen Van Baelen, MD (KU Leuven, Belgium) |
| 10:25am-10:45am | Metastatic Spread in Patients with Mixed ILC/NST: Results from Post-Mortem Tissue Donation Programs |
| 10:45am-11:10am | Coffee Break |
| 11:10am-12:40pm | Case Reports |
| | Chair: Nancy Davidson, MD (Fred Hutch Cancer Center, Seattle, WA) |
| | Presenters: Rachel Jankowitz, MD (University of Pennsylvania, Philadelphia), Kit Lu, MD (UPMC, Harrisburg, PA) Elinor Sawyer, PhD (Kings College London, UK), Dhaval Mehta, MD (UPMC, Monroeville, PA) and Chuck Geyer, MD (NSABP, Pittsburgh, PA), |
| 12:40pm-1:10pm | Discussions of Research Priorities and Potential Collaborations |
| | Chair: Steffi Oesterreich PhD (University of Pittsburgh, PA) |
| | Christine Desmedt , PhD , (KU Leuven, Belgium), Jason Mouabbi, MD , (UT MD Anderson Cancer Center), Patrick Derksen, PhD (UMC Utrecht, Netherlands), Rita Mukhtar MD (UCSF, San Francisco, CA) |
| 1:10pm | Closing Remarks and Boxed Lunch To-Go |